NBA Season Suspended/COVID-19; 3/31 - All Lakers cleared and symptom free (**No politics or racial/ethnic remarks or personal insults**)
Goto page Previous  1, 2, 3 ... 107, 108, 109

 
Post new topic    LakersGround.net Forum Index -> LA Lakers Lounge Reply to topic
View previous topic :: View next topic  
Author Message
lar9149
Star Player
Star Player


Joined: 10 Jul 2010
Posts: 1192

PostPosted: Sat Aug 01, 2020 9:49 am    Post subject:

cal1piggy wrote:
An inhaled formulation of interferon beta, significantly decreased the chances of hospitalized patients developing severe COVID-19 compared to placebo.

SNG001, the inhaled formulation of interferon beta, significantly decreased the chances of hospitalized patients developing severe COVID-19 compared to placebo, according to Synairgen, as reported by FirstWord Pharma.

A total of 221 patients were included in the SG016 study of randomly selected patients; 101 were in-hospital patients with confirmed or suspected COVID-19 virus and 120 patients remained at home.

The patients received either active or placebo treatment that was delivered by mesh nebulizer once daily for up to 14 days. The primary endpoint was the patients’ change in condition during the treatment period.


Active treatment cuts severe disease development dramatically
Synairgen, a UK-based company, reported that compared with placebo the odds of developing severe disease during the treatment period decreased by 79% for hospitalized patients receiving SNG001, and that patients who received SNG001 were more than twice as likely to recover from the virus during the treatment period versus those randomized to placebo.


Importantly, during treatment, the measure of breathlessness was “markedly reduced” in patients who received SNG001 compared to placebo.

“The results confirm our belief that interferon beta…has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus,” Tom Wilkinson, the chief study investigator said.

Synairgen also reported that patients with more severe disease upon hospital admission who were treated with SNG001 had an increased non-significant likelihood of discharge.

The median times to discharge were 6 days and 9 days, respectively, for SNG001-treated patients and placebo patients.

Other observations were that patients in the SNG001 group appeared more than twice as likely to recover by the end of treatment, although the difference did not reach significance, and by day 28, the SNG001-treated patients had significantly better odds of recovery.

Three patients in the placebo group died; no deaths occurred in the SNG001 group.

Synairgen is now working with regulators and other key groups to obtain approval of this potential COVID-19 treatment.

https://www.ophthalmologytimes.com/view/ocular-trauma-in-the-covid-19-era


Awesome share Cal1. Interferon..to me that sounds like a great treatment. Interferon simply signals nearby cells of a virus invasion. Think of it like in the military where they signal nearby bases of an enemy attack..the bases will be better prepared. This sounds like something that should work great and since its inhaled, it can be used by perhaps mild & moderate cases. With a 79% reduction of developing a severe case, that sounds like a big impact.

I am surprised this treatment hasn't been talked about much because Interferon has been used to treat Heptatitis B&C (inflammation of the liver also caused by a virus), although it has to be injected and has severe side effects. Must be why this one is inhaled, which should reduce side effects. The fact that it is inhaled rather than in ..I did find the below article stating its possible use for COVID-19 in May due to a study in Wuhan, China although the study was small

https://www.upi.com/Health_News/2020/05/15/Hepatitis-drug-interferon-alpha-2b-might-treat-COVID-19-effectively/8901589490924/
Back to top
View user's profile Send private message Reply with quote
cal1piggy
Star Player
Star Player


Joined: 19 Jul 2017
Posts: 1991

PostPosted: Sat Aug 01, 2020 4:42 pm    Post subject:

lar9149 wrote:
cal1piggy wrote:
An inhaled formulation of interferon beta, significantly decreased the chances of hospitalized patients developing severe COVID-19 compared to placebo.

SNG001, the inhaled formulation of interferon beta, significantly decreased the chances of hospitalized patients developing severe COVID-19 compared to placebo, according to Synairgen, as reported by FirstWord Pharma.

A total of 221 patients were included in the SG016 study of randomly selected patients; 101 were in-hospital patients with confirmed or suspected COVID-19 virus and 120 patients remained at home.

The patients received either active or placebo treatment that was delivered by mesh nebulizer once daily for up to 14 days. The primary endpoint was the patients’ change in condition during the treatment period.


Active treatment cuts severe disease development dramatically
Synairgen, a UK-based company, reported that compared with placebo the odds of developing severe disease during the treatment period decreased by 79% for hospitalized patients receiving SNG001, and that patients who received SNG001 were more than twice as likely to recover from the virus during the treatment period versus those randomized to placebo.


Importantly, during treatment, the measure of breathlessness was “markedly reduced” in patients who received SNG001 compared to placebo.

“The results confirm our belief that interferon beta…has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus,” Tom Wilkinson, the chief study investigator said.

Synairgen also reported that patients with more severe disease upon hospital admission who were treated with SNG001 had an increased non-significant likelihood of discharge.

The median times to discharge were 6 days and 9 days, respectively, for SNG001-treated patients and placebo patients.

Other observations were that patients in the SNG001 group appeared more than twice as likely to recover by the end of treatment, although the difference did not reach significance, and by day 28, the SNG001-treated patients had significantly better odds of recovery.

Three patients in the placebo group died; no deaths occurred in the SNG001 group.

Synairgen is now working with regulators and other key groups to obtain approval of this potential COVID-19 treatment.

https://www.ophthalmologytimes.com/view/ocular-trauma-in-the-covid-19-era


Awesome share Cal1. Interferon..to me that sounds like a great treatment. Interferon simply signals nearby cells of a virus invasion. Think of it like in the military where they signal nearby bases of an enemy attack..the bases will be better prepared. This sounds like something that should work great and since its inhaled, it can be used by perhaps mild & moderate cases. With a 79% reduction of developing a severe case, that sounds like a big impact.

I am surprised this treatment hasn't been talked about much because Interferon has been used to treat Heptatitis B&C (inflammation of the liver also caused by a virus), although it has to be injected and has severe side effects. Must be why this one is inhaled, which should reduce side effects. The fact that it is inhaled rather than in ..I did find the below article stating its possible use for COVID-19 in May due to a study in Wuhan, China although the study was small

https://www.upi.com/Health_News/2020/05/15/Hepatitis-drug-interferon-alpha-2b-might-treat-COVID-19-effectively/8901589490924/


hi, lar, i also did not think much of interferon before for covid. i guess the inhaled version may be the trick.

yes 79% is huge. if this impact remains intact in a large phase 3, then it is the drug we have been waiting for stopping moderate cases from progressing to critical cases...

now i really want to see what combinations of inhaled interferon b with remdesivisir and dexamethasone do in a large study.
Back to top
View user's profile Send private message Reply with quote
cal1piggy
Star Player
Star Player


Joined: 19 Jul 2017
Posts: 1991

PostPosted: Sat Aug 01, 2020 7:50 pm    Post subject:

bad news on actemra, but we have dexamethasone as an anti-inflammatory that works. now lets hope interfereon beta continues to be near 79%...

Roche’s Phase III COVACTA study of Actemra/RoActemra (tocilizumab) did not meet its primary endpoint of improved clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia. Also, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, there was a positive trend in time to hospital discharge in patients treated with Actemra/RoActemra. The COVACTA study did not identify any new safety signals for Actemra/RoActemra.

https://www.contractpharma.com/content-microsite/covid-19/2020-07-30/roches-phase-iii-trial-of-actemra-in-covid-19-misses-primary-endpoint
Back to top
View user's profile Send private message Reply with quote
lar9149
Star Player
Star Player


Joined: 10 Jul 2010
Posts: 1192

PostPosted: Mon Aug 03, 2020 6:16 am    Post subject:

cal1piggy wrote:
lar9149 wrote:
cal1piggy wrote:
An inhaled formulation of interferon beta, significantly decreased the chances of hospitalized patients developing severe COVID-19 compared to placebo.

SNG001, the inhaled formulation of interferon beta, significantly decreased the chances of hospitalized patients developing severe COVID-19 compared to placebo, according to Synairgen, as reported by FirstWord Pharma.

A total of 221 patients were included in the SG016 study of randomly selected patients; 101 were in-hospital patients with confirmed or suspected COVID-19 virus and 120 patients remained at home.

The patients received either active or placebo treatment that was delivered by mesh nebulizer once daily for up to 14 days. The primary endpoint was the patients’ change in condition during the treatment period.


Active treatment cuts severe disease development dramatically
Synairgen, a UK-based company, reported that compared with placebo the odds of developing severe disease during the treatment period decreased by 79% for hospitalized patients receiving SNG001, and that patients who received SNG001 were more than twice as likely to recover from the virus during the treatment period versus those randomized to placebo.


Importantly, during treatment, the measure of breathlessness was “markedly reduced” in patients who received SNG001 compared to placebo.

“The results confirm our belief that interferon beta…has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus,” Tom Wilkinson, the chief study investigator said.

Synairgen also reported that patients with more severe disease upon hospital admission who were treated with SNG001 had an increased non-significant likelihood of discharge.

The median times to discharge were 6 days and 9 days, respectively, for SNG001-treated patients and placebo patients.

Other observations were that patients in the SNG001 group appeared more than twice as likely to recover by the end of treatment, although the difference did not reach significance, and by day 28, the SNG001-treated patients had significantly better odds of recovery.

Three patients in the placebo group died; no deaths occurred in the SNG001 group.

Synairgen is now working with regulators and other key groups to obtain approval of this potential COVID-19 treatment.

https://www.ophthalmologytimes.com/view/ocular-trauma-in-the-covid-19-era


Awesome share Cal1. Interferon..to me that sounds like a great treatment. Interferon simply signals nearby cells of a virus invasion. Think of it like in the military where they signal nearby bases of an enemy attack..the bases will be better prepared. This sounds like something that should work great and since its inhaled, it can be used by perhaps mild & moderate cases. With a 79% reduction of developing a severe case, that sounds like a big impact.

I am surprised this treatment hasn't been talked about much because Interferon has been used to treat Heptatitis B&C (inflammation of the liver also caused by a virus), although it has to be injected and has severe side effects. Must be why this one is inhaled, which should reduce side effects. The fact that it is inhaled rather than in ..I did find the below article stating its possible use for COVID-19 in May due to a study in Wuhan, China although the study was small

https://www.upi.com/Health_News/2020/05/15/Hepatitis-drug-interferon-alpha-2b-might-treat-COVID-19-effectively/8901589490924/


hi, lar, i also did not think much of interferon before for covid. i guess the inhaled version may be the trick.

yes 79% is huge. if this impact remains intact in a large phase 3, then it is the drug we have been waiting for stopping moderate cases from progressing to critical cases...

now i really want to see what combinations of inhaled interferon b with remdesivisir and dexamethasone do in a large study.



Pretty much hit the nail on the head there. Although once interferon is FDA approved, I am confident doctors will use the above combo without a study.

The taught is

mild-moderate cases give inhaled interferon b--resulting in a 79% reduction of progressing to severe

If they still progress to severe, give remdesivirisir and dexamethasone..hard to know the reduction in mortality here, the below article says 62% but that is patients who didn't need mechanical ventilation and on remdesivirisir only.

https://time.com/5865491/remdesivir-covid-study/

Put those together and you talking a strong strong reduction on mortality (79% up front than maybe a 60% for those who still progress)..even if a large study isn't completed on this combo, I think that will be the regimen of medical care for these patients.
Back to top
View user's profile Send private message Reply with quote
cal1piggy
Star Player
Star Player


Joined: 19 Jul 2017
Posts: 1991

PostPosted: Mon Aug 03, 2020 7:43 am    Post subject:

lar9149 wrote:
cal1piggy wrote:
lar9149 wrote:
cal1piggy wrote:
An inhaled formulation of interferon beta, significantly decreased the chances of hospitalized patients developing severe COVID-19 compared to placebo.

SNG001, the inhaled formulation of interferon beta, significantly decreased the chances of hospitalized patients developing severe COVID-19 compared to placebo, according to Synairgen, as reported by FirstWord Pharma.

A total of 221 patients were included in the SG016 study of randomly selected patients; 101 were in-hospital patients with confirmed or suspected COVID-19 virus and 120 patients remained at home.

The patients received either active or placebo treatment that was delivered by mesh nebulizer once daily for up to 14 days. The primary endpoint was the patients’ change in condition during the treatment period.


Active treatment cuts severe disease development dramatically
Synairgen, a UK-based company, reported that compared with placebo the odds of developing severe disease during the treatment period decreased by 79% for hospitalized patients receiving SNG001, and that patients who received SNG001 were more than twice as likely to recover from the virus during the treatment period versus those randomized to placebo.


Importantly, during treatment, the measure of breathlessness was “markedly reduced” in patients who received SNG001 compared to placebo.

“The results confirm our belief that interferon beta…has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus,” Tom Wilkinson, the chief study investigator said.

Synairgen also reported that patients with more severe disease upon hospital admission who were treated with SNG001 had an increased non-significant likelihood of discharge.

The median times to discharge were 6 days and 9 days, respectively, for SNG001-treated patients and placebo patients.

Other observations were that patients in the SNG001 group appeared more than twice as likely to recover by the end of treatment, although the difference did not reach significance, and by day 28, the SNG001-treated patients had significantly better odds of recovery.

Three patients in the placebo group died; no deaths occurred in the SNG001 group.

Synairgen is now working with regulators and other key groups to obtain approval of this potential COVID-19 treatment.

https://www.ophthalmologytimes.com/view/ocular-trauma-in-the-covid-19-era


Awesome share Cal1. Interferon..to me that sounds like a great treatment. Interferon simply signals nearby cells of a virus invasion. Think of it like in the military where they signal nearby bases of an enemy attack..the bases will be better prepared. This sounds like something that should work great and since its inhaled, it can be used by perhaps mild & moderate cases. With a 79% reduction of developing a severe case, that sounds like a big impact.

I am surprised this treatment hasn't been talked about much because Interferon has been used to treat Heptatitis B&C (inflammation of the liver also caused by a virus), although it has to be injected and has severe side effects. Must be why this one is inhaled, which should reduce side effects. The fact that it is inhaled rather than in ..I did find the below article stating its possible use for COVID-19 in May due to a study in Wuhan, China although the study was small

https://www.upi.com/Health_News/2020/05/15/Hepatitis-drug-interferon-alpha-2b-might-treat-COVID-19-effectively/8901589490924/


hi, lar, i also did not think much of interferon before for covid. i guess the inhaled version may be the trick.

yes 79% is huge. if this impact remains intact in a large phase 3, then it is the drug we have been waiting for stopping moderate cases from progressing to critical cases...

now i really want to see what combinations of inhaled interferon b with remdesivisir and dexamethasone do in a large study.



Pretty much hit the nail on the head there. Although once interferon is FDA approved, I am confident doctors will use the above combo without a study.

The taught is

mild-moderate cases give inhaled interferon b--resulting in a 79% reduction of progressing to severe

If they still progress to severe, give remdesivirisir and dexamethasone..hard to know the reduction in mortality here, the below article says 62% but that is patients who didn't need mechanical ventilation and on remdesivirisir only.

https://time.com/5865491/remdesivir-covid-study/

Put those together and you talking a strong strong reduction on mortality (79% up front than maybe a 60% for those who still progress)..even if a large study isn't completed on this combo, I think that will be the regimen of medical care for these patients.


yes, i worked nonstop for a few weeks on our covid project. when i stuck my head out, there is good covid news.

dexamethasone may not have good results for seniors though.

lets hope the 79% phase 2 result stays high in the phase 3 trial.

it is interesting that there are foreign companies making remdesivir but we are not importing it... i would imagine they have more production capacity than gilead. they licensed it but there were no supply requirements coming back?

next up would be some results from regeneron and other monoclonal antibodies used sort of like a vaccine.

turns out my college classmate is sort of the chief science person at a mRNA vaccine company. she said that it is hit and miss for vaccines to work as it depends on which part of the viral protein will the antibodies bind to...
Back to top
View user's profile Send private message Reply with quote
Display posts from previous:   
Post new topic    LakersGround.net Forum Index -> LA Lakers Lounge All times are GMT - 8 Hours
Goto page Previous  1, 2, 3 ... 107, 108, 109
Page 109 of 109
Jump to:  

 
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum






Graphics by uberzev
© 1995-2018 LakersGround.net. All Rights Reserved. Privacy Policy. Terms of Use.
LakersGround is an unofficial news source serving the fan community since 1995.
We are in no way associated with the Los Angeles Lakers or the National Basketball Association.


Powered by phpBB